Selux Diagnostics receives BARDA funding to speed development of rapid AST platform

The Biomedical Advanced Research and Development Authority (BARDA) has awarded Selux Diagnostics $9.6 million to fund its development of a next-generation phenotyping (NGP) platform to treat superbug infections and combat antibiotic resistance.

The $9.6 million is the third funding tranche the company has received from BARDA as part of the company’s milestone-based contract. BARDA has provided Selux $30.4 million in funding to date.

“BARDA has offered strong support in the development of the Selux NGP platform and has led the way in the successful government-private sector collaboration to solve one of the world’s toughest health challenges — antibiotic resistance,” said Selux CEO Steve Lufkin. “This leadership is especially vital now, as new data indicate the antibiotic resistance crisis is even more threatening than previously understood. BARDA is leveraged by our private investor support to transform microbiology and put our life-saving capabilities into action.”

Get the full story on our WTWH Media sister site R&D World.